Drug
Fingolimod clinical trials
Also written FTY720 and Gilenya.
- studies test it
- 75
- open now
- 8
- in phase 3
- 24
- first study started
- 2002
Keep track of what changes. Save the fingolimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
75 studies that test it; most in 2012 (9)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 4 |
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 1 |
| 2008 | 5 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 9 |
| 2013 | 9 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 7
- Phase 2
- 21
- Phase 3
- 24
- Phase 4
- 23
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 54 · Other 21
Novartis Pharmaceuticals (38) · Novartis (12) · Mayo Clinic (2) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2) · Wake Forest University Health Sciences (1) · Alembic Pharmaceuticals Ltd. (1) · Genuine Research Center, Egypt (1) · Indiana University (1)
Often tested with
Tested in the same studies.
Dimethyl Fumarate (2) · Mycophenolic Acid (1) · Diroximel fumarate (1) · Ublituximab (1) · Natalizumab (1)
Studies
Open first, then newest update. How each study uses fingolimod is read from its arms, and is right about nine times in ten.
Testing it · 75
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingPhase 2/3TG Therapeutics, Inc.NCT07220252Written as Fingolimod
- Fingolimod for Type 2 Diabetes MellitusRecruitingPhase 4General Hospital of Shenyang Military RegionNCT05307731Written as Fingolimod
- Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple SclerosisRecruitingPhase 4Novartis PharmaceuticalsNCT04480853Written as Fingolimod
- Phase 2 Study of Fingolimod in Lung CancersRecruitingPhase 2Medical University of South CarolinaNCT06424067Written as Fingolimod 0.5 milligram (mg) [Gilenya]
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Not yet recruitingPhase 3BiogenNCT07483632Written as Fingolimod
- Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney TransplantationEnrolling by invitationPhase 2The Methodist Hospital Research InstituteNCT05285878Written as Fingolimod
- Fingolimod in Minimal Invasive Treatment of Intracerebral HemorrhageNot yet recruitingPhase 1/2Tang-Du HospitalNCT06087965Written as Fingolimod
- Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic StrokeRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04675762Written as Fingolimod
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT01892722Written as Fingolimod
- Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) PatientsCompletedPhase 4Novartis PharmaceuticalsNCT04667949Written as Fingolimod 0.5mg
- Fingolimod as a Treatment of Cerebral Edema After Intracerebral HemorrhageCompletedEarly Phase 1Wake Forest University Health SciencesNCT04088630Written as Fingolimod
- Fingolimod in Treating Patients With Chemotherapy-Induced NeuropathyCompletedEarly Phase 1Mayo ClinicNCT03943498Written as Fingolimod
- Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast CancerCompletedPhase 1Mayo ClinicNCT03941743Written as Fingolimod
- Fingolimod in Endovascular Treatment of Ischemic StrokeStatus unknownPhase 2Ning Wang, MD., PhD.NCT04629872Written as Fingolimod
- Oral Bio-equivalence StudyCompletedPhase 1Alembic Pharmaceuticals Ltd.NCT05145621Written as Fingolimod 0.5 mg capsules- Test drug
- A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg FingolimodCompletedPhase 4Novartis PharmaceuticalsNCT03257358Written as Fingolimod
- Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic StrokeWithdrawnPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT02956200Written as Fingolimod
- Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisCompletedPhase 3Novartis PharmaceuticalsNCT01201356Written as Fingolimod
- Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular RisksCompletedPhase 4Novartis PharmaceuticalsNCT02232061Written as Fingolimod
- Revascularization Pretreated With Fingolimod in Acute StrokeStatus unknownNot applicableThe Affiliated Hospital of Xuzhou Medical UniversityNCT04718064Written as Fingolimod
See all 75 studies that test fingolimod →
Given in every arm · 2 — fingolimod is usual care beside what is tested
- Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis PatientsCompletedPhase 2/3Isfahan University of Medical SciencesNCT02939079Written as Fingolimod
- Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With DepressionTerminatedPhase 4Novartis PharmaceuticalsNCT01436643Written as Fingolimod
As the comparator · 5 — what is tested is compared with fingolimod
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisRecruitingPhase 3Bristol-Myers SquibbNCT06408259Written as Fingolimod
- A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Active, not recruitingPhase 3Hoffmann-La RocheNCT05123703Written as Fingolimod
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04926818Written as Fingolimod
- Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsTerminatedPhase 4BiogenNCT02342704Written as fingolimod
- A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303CompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02193217Written as Fingolimod
Codes
What other systems call fingolimod · ClinicalTrials.gg INT006551
- MeSH (NLM) D000068876Fingolimod HydrochlorideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3QN8BYN5QFFINGOLIMODConfirmed FDA, NLM, Wikidata
- RxNorm 1012892Confirmed FDA, Wikidata
- Wikidata Q425137fingolimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74202FingolimodOne source FDA
- DrugBank DB08868One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068876 | Fingolimod Hydrochloride | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3QN8BYN5QF | FINGOLIMOD | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1012892 | — | Confirmed FDA, Wikidata |
| Wikidata | Q425137 | fingolimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74202 | Fingolimod | One source FDA |
| DrugBank | DB08868 | — | One source Wikidata |
Also registered as fingolimod hydrochloride (UNII G926EC510T · RxNorm 1012891).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.